{"authors": [["Cafaro", "Aurelio", "A", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Sgadari", "Cecilia", "C", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Picconi", "Orietta", "O", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Tripiciano", "Antonella", "A", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Moretti", "Sonia", "S", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Francavilla", "Vittorio", "V", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Pavone Cossut", "Maria Rosaria", "MR", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Butt\u00f2", "Stefano", "S", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Cozzone", "Giovanni", "G", "c Vaxxit, Executive Office , Rome , Italy."], ["Ensoli", "Fabrizio", "F", "b Laboratory of Clinical Pathology and Microbiology, San Gallicano Institute , Istituti Fisioterapici Ospitalieri , Rome , Italy."], ["Monini", "Paolo", "P", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."], ["Ensoli", "Barbara", "B", "a National HIV/AIDS Research Center , Istituto Superiore di Sanit\u00e0 , Rome , Italy."]], "date": "2017-12-22", "id": "29243498", "text": "In spite of its success at suppressing HIV replication, combination antiretroviral therapy (cART) only partially reduces immune dysregulation and loss of immune functions. These cART-unmet needs appear to be due to persistent virus replication and cell-to-cell transmission in reservoirs, and are causes of increased patients' morbidity and mortality. Up to now, therapeutic interventions aimed at cART-intensification by attacking the virus reservoir have failed. Areas covered: We briefly review the rationale and clinical development of Tat therapeutic vaccine in cART-treated subjects in Italy and South Africa (SA). Vaccination with clade-B Tat induced cross-clade neutralizing antibodies, immune restoration, including CD4+ T cell increase particularly in low immunological responders, and reduction of proviral DNA. Phase III efficacy trials in SA are planned both in adult and pediatric populations. Expert commentary: We propose the Tat therapeutic vaccine as a pathogenesis-driven intervention that effectively intensifies cART and may lead to a functional cure and provide new perspectives for prevention and virus eradication strategies.", "doi": "10.1080/14760584.2018.1418666", "title": "\"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies\".", "journal": ["Expert review of vaccines", "Expert Rev Vaccines"]}